GlassScriptPhysician profile
Charlene M Jordan
NPI 1679800643
$7,842.44
in general payments reported to CMS, 2019-2025
53 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $1,075 · 2023: $1,190 · 2024: $2,492 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065 · Long Term Medical Supply Or Device Loan: $2,283 · Education: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.77 |
| Long Term Medical Supply Or Device Loan | $2,282.65 |
| Education | $776.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,113.83 | 2021-2025 | |
| Incyte Corporation | $560.12 | 2022-2025 | Jakafi, Monjuvi, Jakafi |
| Abbvie INC. | $485.03 | 2021-2025 | |
| Lilly USA, LLC | $253.05 | 2021-2024 | Jaypirca |
| Astellas Pharma US INC | $239.13 | 2021-2024 | Xtandi, Padcev |
| Amgen INC. | $233.29 | 2021-2023 | Lumakras |
| Janssen Biotech, INC. | $210.70 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $204.27 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Pfizer INC. | $204.16 | 2021-2025 | |
| Daiichi Sankyo INC. | $182.78 | 2021-2025 | Enhertu, Datroway |
| Seagen INC. | $151.10 | 2021-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $146.19 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Ipsen Biopharmaceuticals, INC | $139.94 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $139.36 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $117.62 | 2023-2025 | Keytruda, Welireg, Lynparza |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.91 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.32 | 2021-2025 | Ninlaro, Iclusig, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $76.66 | 2021-2024 | Libtayo |
| Beigene USA, INC. | $59.77 | 2024-2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $57.39 | 2024-2025 | Itovebi, Lunsumio, Polivy |
| Genzyme Corporation | $57.39 | 2021-2022 | |
| Tersera Therapeutics LLC | $56.42 | 2024-2025 | Xermelo, Quzyttir |
| Alnylam Pharmaceuticals INC. | $54.43 | 2024-2025 | Givlaari |
| Gilead Sciences, INC. | $52.56 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $49.15 | 2024 | Zejula |
| Mirati Therapeutics, INC. | $45.54 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $43.85 | 2023-2024 | Xpovio |
| Novocure INC. | $43.00 | 2024-2025 | Optune, Optune Gio |
| Taiho Oncology, INC. | $41.52 | 2021-2025 | |
| Celgene Corporation | $39.97 | 2023-2024 | Reblozyl |
| Spectrum Pharmaceuticals INC. | $38.77 | 2024-2025 | Rolvedon |
| Array Biopharma INC | $38.14 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Geron Corporation | $30.62 | 2025 | Rytelo |
| Tempus Ai, INC | $29.53 | 2025 | Xt Cdx |
| Exelixis INC. | $28.86 | 2022 | |
| Servier Pharmaceuticals LLC | $23.49 | 2025 | |
| Genmab U.S., INC. | $22.86 | 2024 | Epkinly |
| Accord Healthcare, INC. | $22.46 | 2025 | |
| Aveo Pharmaceuticals, INC. | $22.35 | 2025 | |
| Cti Biopharma Corp. | $21.02 | 2023 | Vonjo |
| Jazz Pharmaceuticals INC. | $20.55 | 2025 | |
| Blueprint Medicines Corporation | $19.91 | 2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $19.73 | 2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $19.05 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $18.68 | 2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $18.41 | 2024 | Qinlock, Tgct |
| Adc Therapeutics America, INC. | $18.28 | 2023 | |
| Sobi, INC | $17.11 | 2022 | |
| Progenics Pharmaceuticals, INC. | $17.05 | 2024 | |
| Coherus Oncology, INC. | $16.59 | 2024 | |
| Pharmacosmos Therapeutics INC. | $15.73 | 2025 | Monoferric |
| Dova Pharmaceuticals | $14.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.